Table 3.
Predictors | OR | CI | OR | CI | OR | CI | OR | CI | OR | CI | OR | CI | OR | CI |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(Intercept) | 0.06 | 0.04–0.11 | 0.02 | 0.00–0.06 | 0.00 | 0.00–0.01 | 0.05 | 0.00–76.41 | 0.03 | 0.00–11.90 | 0.03 | 0.00–13.26 | 0.03 | 0.00–14.88 |
Treatment group | ||||||||||||||
Control group | 5.93* | 1.51–39.26 | 7.38* | 1.81–50.29 | 6.89* | 1.68– 7.09 | 6.93* | 1.68– 7.39 | 6.32* | 1.51– 3.56 | 6.09* | 1.45–42.12 | ||
Comorbidities | 1.57*** | 1.17–2.20 | 1.66** | 1.21–2.38 | 1.64** | 1.20–2.37 | 1.68** | 1.22–.43 | 1.68** | 1.22–2.43 | ||||
Age | 0.95 | 0.85–1.05 | 0.95 | 0.85–1.06 | 0.95 | 0.85–.06 | 0.95 | 0.85–1.06 | ||||||
BMI | 1.02 | 0.90–1.15 | 1.02 | 0.90–1.15 | 1.01 | 0.89–1.15 | ||||||||
CLD Yes | ||||||||||||||
CLD No | 0.64 | 0.23–1.58 | 0.63 | 0.22–1.59 | ||||||||||
Vit.D Levels | ||||||||||||||
1.00 | 0.95–1.05 | |||||||||||||
Female | ||||||||||||||
Male | 1.05 | 0.28–8.69 | ||||||||||||
N | 200 | 200 | 200 | 200 | 200 | 200 | 197 | |||||||
R2 Tjur | 0.00 | 0.03 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | |||||||
Log likelihood | −45.39 | −41.96 | −37.39 | −36.86 | −36.81 | −36.34 | −36.00 | |||||||
Akaike Inf. Crit. | 92.79 | 87.92 | 80.77 | 81.73 | 83.61 | 84.69 | 87.99 |
OR refers to Odds Ratios. CI are 95% Confience Intervals.
p < 0.05;
p < 0.01;
p < 0.001.